ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

February 28, 2027

Study Completion Date

May 30, 2027

Conditions
Glioblastoma Multiforme (GBM)
Interventions
DRUG

ADI-PEG 20

Investigational Medicine

DRUG

Temozolomide

Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.

DRUG

Placebo

Investigational Medicine

Trial Locations (10)

13620

Seoul National University Bundang Hospital, Gyeonggi-do

58128

Chonnam National University Hwasun Hospital, Hwasun-gun

100229

National Taiwan University Hospital, Taipei

204201

Chang Gung-Medical Foundation-Keelung (CGMF-KL), Keelung

251404

Mackay Memorial Hospital-Tamsui Branch, New Taipei City

333423

Chang Gung Memorial Hospital, Linkou Branch, Taoyuan District

833401

Chang Gung Medical Foundation-Kaohsiung, Kaohsiung City

03080

Seoul National University Hospital, Seoul

06591

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul

03722

Severance Hospital Yonsei University, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Polaris Group

INDUSTRY

NCT04587830 - ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter